List of Excipients in Branded Drug Xtandi

XTANDI Excipient Strategy and Commercial Opportunities in Enzalutamide Formulation

Last updated: September 24, 2026

XTANDI, the enzalutamide brand marketed by Astellas Pharma US and Pfizer, has two oral dosage forms in the United States: 40 mg and 80 mg film-coated tablets, and 40 mg liquid-filled capsules. The primary excipient opportunity is a generic or differentiated tablet that matches XTANDI’s dissolution and bioavailability while avoiding unnecessary formulation complexity. Lipid-based capsule technology, solubility-enhancing systems, and specialty excipients remain relevant for lifecycle management, but the largest near-term commercial opportunity is supply to generic manufacturers preparing for U.S. entry after the core patent estate expires.

What excipients are used in XTANDI tablets and capsules?

XTANDI uses different excipient systems for its tablet and capsule presentations. The tablet is a conventional solid oral dosage form. The capsule uses a lipid-based liquid fill to support delivery of the poorly water-soluble active pharmaceutical ingredient.

Dosage form	Strengths	Formulation type	Key excipient categories
Film-coated tablet	40 mg and 80 mg	Immediate-release compressed tablet	Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate, film-coating excipients
Liquid-filled capsule	40 mg	Lipid-based liquid fill	Caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, gelatin capsule shell, colorants and printing components

The inactive ingredients identified in the U.S. prescribing information include caprylocaproyl polyoxylglycerides and butylated hydroxyanisole for the capsule formulation. The tablet uses standard direct-compression and film-coating excipient classes, including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, sodium lauryl sulfate and magnesium stearate. Exact supplier grades and processing parameters are not disclosed in the commercial label and can materially affect dissolution performance. (Astellas Pharma US, 2024)

Why does enzalutamide require formulation support?

Enzalutamide has limited aqueous solubility. Its formulation must support consistent dissolution, absorption and exposure despite the drug’s hydrophobic chemical structure. The capsule uses a lipid vehicle, while the tablet relies on particle dispersion, wetting, disintegration and compressed-matrix control.

The formulation challenge is commercially important because an excipient substitution can affect:

• Dissolution across physiologic pH conditions
• Bioequivalence against the reference product
• Tablet hardness and friability
• Capsule-fill uniformity
• Chemical stability
• Moisture sensitivity
• Manufacturing throughput
• Food-effect behavior
• Batch-to-batch release specifications

Which excipient strategy is most attractive for generic XTANDI?

The most practical generic strategy is a conventional immediate-release tablet with Q1/Q2 matching or a narrowly justified excipient variation. A Q1/Q2 approach uses the same inactive ingredients in the same qualitative and quantitative composition, subject to the applicable FDA requirements. This can reduce regulatory risk and simplify comparative dissolution work.

Three formulation routes are commercially relevant:

Strategy	Technical benefit	Regulatory position	Commercial attractiveness
Reference-matched tablet	Lowest formulation deviation	Strongest 505(j) positioning if performance matches	High
Lipid-based capsule	May improve wetting and solubilization	Requires stronger product-specific equivalence package	Moderate
Differentiated solubility platform	Potentially improves manufacturability or dose flexibility	May require additional studies and create new IP	Moderate to high for lifecycle products

A generic manufacturer should generally prioritize the tablet rather than reproduce the lipid-filled capsule. The tablet has fewer specialized processing steps, fewer capsule-shell variables and a simpler scale-up pathway. The capsule remains relevant where a company owns a lipid formulation platform or seeks a non-generic lifecycle product.

What tablet excipients are most commercially relevant?

Microcrystalline cellulose is the principal structural excipient opportunity. It controls tablet compression, porosity and mechanical strength. Different particle-size distributions and moisture grades can change enzalutamide dissolution.

Croscarmellose sodium supports tablet breakup. Its level, distribution and compaction history can affect disintegration and drug release.

Sodium lauryl sulfate is particularly relevant because it can improve wetting of a hydrophobic active. It may also affect dissolution variability and compatibility with other excipients.

Colloidal silicon dioxide can improve powder flow and reduce segregation. Magnesium stearate supports lubrication but excessive or prolonged lubrication can slow wetting and dissolution.

The commercial opportunity is therefore concentrated in high-performance grades rather than novel excipient molecules. Suppliers that can provide consistent compaction, low variability and documented regulatory support are better positioned than suppliers offering undifferentiated commodity materials.

What formulation technologies could improve enzalutamide delivery?

Lipid-based formulations

Caprylocaproyl polyoxylglycerides are already used in the XTANDI capsule. A generic or lifecycle developer could evaluate self-emulsifying drug-delivery systems, mixed lipid systems and surfactant combinations.

The main advantages are:

• Improved wetting of enzalutamide
• Reduced dependence on drug particle size
• Potentially faster apparent dissolution
• Compatibility with softgel or hard-shell liquid-filled capsules

The principal risks are fill-weight control, capsule-shell compatibility, oxidation, precipitation after dilution and food-effect differences. Butylated hydroxyanisole indicates the relevance of oxidative stability in the capsule system.

Amorphous solid dispersions

An amorphous solid dispersion could improve apparent solubility by maintaining enzalutamide in a higher-energy amorphous state. Polymer candidates would require screening for precipitation inhibition, chemical compatibility and physical stability.

Commercial barriers include:

• Residual solvent control
• Spray-drying or hot-melt-extrusion capital
• Amorphous-to-crystalline conversion
• Long-term stability
• More complex bioequivalence justification

This route is more attractive for a differentiated product than for a first generic because conventional XTANDI tablets already establish a viable oral product.

Nanocrystal or micronized API systems

Particle-size reduction can improve dissolution without introducing a new polymeric matrix. It may be suitable for a tablet platform using wetting agents and disintegrants.

The principal manufacturing risks are particle agglomeration, electrostatic behavior, content uniformity and dissolution sensitivity to milling conditions. A controlled API particle-size specification can become an important manufacturing and supply-chain requirement.

Modified-release or pediatric products

Modified-release enzalutamide has limited obvious commercial value because the approved product is an immediate-release oral therapy and the target population is largely adult. Pediatric formulations could have limited value in specific indications but would require clinical and regulatory justification.

A smaller tablet, multiparticulate system or oral suspension could have commercial relevance if dosing flexibility becomes clinically important. The existing XTANDI label instructs patients to swallow tablets or capsules whole, which leaves room for a differentiated administration format but does not by itself establish market demand. (Astellas Pharma US, 2024)

What patents protect XTANDI and its formulation?

The core U.S. enzalutamide patent estate has historically included composition-of-matter and related patent protection associated with the enzalutamide molecule and androgen-receptor modulators. The principal U.S. patent commonly identified in connection with XTANDI is U.S. Patent No. 7,709,517. Related patents and regulatory exclusivity may affect the effective timing of generic entry. The FDA Orange Book remains the controlling source for listed patents and pediatric exclusivity information. (U.S. Food and Drug Administration, 2024a)

Protection category	Relevance to excipient strategy
Composition-of-matter patent	Can block commercial sale regardless of excipient choice until expiry or successful challenge
Method-of-use patent	May require a label carve-out or non-infringing indication strategy
Formulation patent	Could restrict a specific lipid, tablet or delivery system
Regulatory exclusivity	Can delay approval even if formulation patents are absent
Manufacturing patent	May affect API or intermediate sourcing rather than finished dosage form

An excipient substitution does not avoid a composition-of-matter patent. It becomes legally relevant only after the active-ingredient patent barrier no longer prevents commercial sale, or where a company is pursuing a Paragraph IV challenge or another legally available entry strategy.

Are XTANDI formulation patents the main generic barrier?

No. For most generic applicants, the dominant barrier is the active-ingredient patent and the timing of Paragraph IV litigation or settlement. A formulation design-around can reduce infringement exposure for a listed formulation patent, but it does not eliminate the need to address the core enzalutamide patent estate.

A differentiated excipient system can create new patent protection for a follow-on product. Potential claim areas include:

• Specific lipid-to-drug ratios
• Particle-size distributions
• Amorphous solid-dispersion compositions
• Stabilized liquid fills
• Dissolution profiles
• Low-dose or high-dose tablet configurations
• Manufacturing processes
• Improved storage stability

Claims must provide a technical distinction over the XTANDI label and published formulation art. Broad claims to conventional excipients are difficult to sustain without a measurable technical effect.

When does XTANDI lose exclusivity and when could generics launch?

The commercial timing depends on the Orange Book-listed patents, pediatric exclusivity, any court judgment and any settlement between the reference sponsor and generic applicants. U.S. patent records identify the core protection as extending into 2027, subject to patent-term adjustment and regulatory details. Generic applicants commonly use an ANDA Paragraph IV certification to challenge listed patents before expiration. (U.S. Patent and Trademark Office, 2024; U.S. Food and Drug Administration, 2024a)

Event	Commercial effect
ANDA filing with Paragraph IV certification	Creates potential patent litigation and an early-entry pathway
Notice of Paragraph IV certification	Can trigger a 45-day period for the sponsor to file suit
Patent litigation	May impose a 30-month stay of approval under applicable conditions
Settlement agreement	Can establish an agreed generic launch date
Core patent expiry	Removes the principal composition barrier
Pediatric exclusivity expiry	Can extend the effective regulatory block by six months
First approved ANDA	May receive 180-day first-filer exclusivity if statutory conditions are met

The exact generic launch date should be assessed from the current Orange Book, FDA approval records, court docket and any public settlement agreement. A formulation supplier should align capacity investment with the earliest legally permitted launch window, not simply the nominal patent expiration date.

Which companies are challenging XTANDI exclusivity?

Generic companies have pursued enzalutamide development because XTANDI has a large oncology market and a technically manageable oral dosage form. Publicly disclosed Paragraph IV activity, ANDA approvals and litigation records should be tracked through FDA records and federal court dockets.

The most relevant competitive groups are:

1. Large generic manufacturers with established oncology portfolios.
2. Indian and European manufacturers with controlled-release and lipid-formulation capabilities.
3. Contract development and manufacturing organizations supplying bioequivalent tablets.
4. Specialty pharmaceutical companies pursuing low-cost oncology products in emerging markets.

The commercial contest is likely to focus on launch timing, API security, manufacturing cost and pharmacy-channel access rather than major differences in excipient composition.

What FDA regulatory pathway applies to generic enzalutamide?

A conventional generic tablet would normally use the abbreviated new drug application pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, satisfy chemistry, manufacturing and controls requirements, and address all applicable patent certifications.

A 505(j) applicant should expect scrutiny of:

• Strength and dosage form
• Assay and content uniformity
• Dissolution profiles
• Impurities and degradants
• Stability under ICH conditions
• Bioequivalence
• Excipient safety and quantity
• Container-closure performance
• Labeling consistency

A novel formulation with a materially different excipient system may be less suitable for an ANDA. It could require a 505(b)(2) strategy if the product relies on new formulation, delivery or clinical-performance claims that cannot be bridged through standard generic evidence.

What commercial opportunities exist for excipient suppliers?

Reference-matched tablet supply

The largest opportunity is supply of microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, sodium lauryl sulfate, magnesium stearate and film-coating systems to generic manufacturers.

Value drivers include:

• Low extractables and leachables risk
• Reliable global supply
• Grade consistency
• Regulatory documentation
• Low variability in dissolution
• Technical support during scale-up
• Compatibility with high-speed compression

Lipid excipient systems

Suppliers of caprylocaproyl polyoxylglycerides, medium-chain glycerides, surfactants and antioxidants can target capsule developers and lifecycle reformulation programs.

A supplier with prequalified lipid blends can reduce formulation screening time. The strongest commercial position would combine excipient supply with formulation development, analytical support and scale-up services.

Film-coating systems

Ready-to-use film coatings can reduce manufacturing complexity and support color differentiation between 40 mg and 80 mg strengths. Suppliers can compete through coating uniformity, low processing temperatures and global regulatory files.

Co-processed excipients

Co-processed fillers, binders and disintegrants could improve flow and compression in a direct-compression enzalutamide tablet. The commercial case depends on demonstrating equivalent or superior dissolution without creating a new regulatory burden.

How strong is the XTANDI formulation opportunity compared with competing androgen-receptor drugs?

Product	Active ingredient	Dosage-form opportunity	Main formulation issue
XTANDI	Enzalutamide	Immediate-release tablet and lipid-filled capsule	Poor aqueous solubility
ERLEADA	Apalutamide	Immediate-release tablet	Solid-state and dissolution control
NUBEQA	Darolutamide	Film-coated tablet	Solubility and dose burden
ZYTIGA	Abiraterone acetate	Tablet	Food effect and bioavailability
ORGOVYX	Relugolix	Film-coated tablet	Absorption, interactions and solid-state control

XTANDI is attractive because it combines a high-value oncology indication with a relatively conventional tablet presentation. ZYTIGA has a stronger food-effect and formulation history, while NUBEQA and ERLEADA compete in the same androgen-receptor pathway but have separate patent and clinical-market dynamics.

The main commercial limitation is that excipient differentiation alone is unlikely to command a large premium in a generic market. The strongest opportunity is a platform that lowers manufacturing cost, improves dissolution robustness or enables a legally distinct lifecycle product.

What revenue exposure is linked to XTANDI generic entry?

XTANDI is a major product for Astellas and contributes materially to the company’s oncology revenue. Generic entry would likely create a rapid price decline in the United States, with the magnitude determined by the number of approved suppliers, first-filer exclusivity and payer substitution.

Revenue erosion typically progresses through:

1. Initial generic entry with limited supplier competition.
2. Price reductions after additional ANDA approvals.
3. Increased substitution through pharmacy and payer channels.
4. Continued branded demand in selected markets or for patients stabilized on therapy.
5. International erosion based on local patent and reimbursement rules.

For excipient companies, the opportunity shifts from branded-product supply to a larger but lower-margin generic volume market. Capacity planning should account for price compression and multiple regional suppliers.

Key Takeaways

• XTANDI uses a lipid-filled 40 mg capsule and 40 mg and 80 mg film-coated tablets.
• The most practical generic strategy is a reference-matched or closely matched immediate-release tablet.
• Microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate and magnesium stearate are the most relevant tablet excipient categories.
• Lipid excipients remain attractive for capsule development and differentiated lifecycle products.
• Excipient substitution does not avoid enzalutamide composition-of-matter patents.
• The core U.S. patent barrier extends into 2027, subject to Orange Book data, patent-term adjustment, pediatric exclusivity and litigation outcomes.
• Generic manufacturers will compete primarily on launch timing, API access, dissolution robustness and cost.
• Excipient suppliers with regulatory files, formulation support and global supply capacity have the strongest commercial position.
• A novel excipient system is more commercially compelling for a 505(b)(2) or lifecycle product than for a first 505(j) generic.

FAQs

Can a generic XTANDI tablet use different excipients?

Yes. A generic applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality and performance. A reference-matched formulation generally reduces development risk.

Is caprylocaproyl polyoxylglycerides a required XTANDI excipient?

No. It is part of the XTANDI capsule formulation, but a generic manufacturer may pursue a tablet or another capsule system if the product satisfies applicable regulatory and bioequivalence requirements.

Does XTANDI require a lipid formulation for adequate absorption?

No. XTANDI is marketed in both a lipid-filled capsule and a tablet. The tablet demonstrates that a lipid vehicle is not the only viable commercial formulation approach.

Can an excipient supplier patent an enzalutamide formulation?

Yes. Patent protection may be available for a novel composition, ratio, process, stability profile or delivery system that satisfies patentability requirements. Conventional substitution of one standard excipient for another is unlikely to support strong broad claims without unexpected technical advantages.

What is the best commercial entry point for an excipient company?

The strongest entry point is a regulatory-supported excipient package for generic immediate-release tablets, followed by lipid-based formulation services for capsule or lifecycle development. Ready-to-use film coatings and co-processed direct-compression systems are secondary opportunities.

References

1. Astellas Pharma US, Inc. (2024). XTANDI (enzalutamide) capsules and tablets: U.S. prescribing information.
2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application submissions: Patent certification and exclusivity provisions.
4. U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent No. 7,709,517 and related enzalutamide patent records.
5. U.S. Food and Drug Administration. (2024c). Inactive ingredient database.